Combined therapy with an aziridine derivative NSC 200724 (AB182) and radiation on an experimental leukemia.
D000818:Animals; D001388:Aziridines / Q000008:administration & dosage / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D005260:Female; D007941:Leukemia P388 / Q000188:drug therapy* / Q000532:radiotherapy; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D011867:Radioisotope Teletherapy
D001388:Aziridines; D001389:Azirines; D011838:Radiation-Sensitizing Agents; C023504:AB-182